HYPERPROLACTINAEMIA

✓ Medically ReviewedDISEASEID: MDBT0276🚨 TRIAGE: ROUTINEICD-10: E22.1

📖

Definition

CLINICAL DEFINITION

Hyperprolactinaemia is a condition characterised by serum prolactin concentrations exceeding the upper limit of the laboratory reference range, most commonly defined in adults as greater than 15–20 micrograms/L (ng/mL), with sex-specific cut-offs frequently cited as approximately 25 micrograms/L in women and 20 micrograms/L in men. It may arise from physiological, pharmacological, pathological, or idiopathic causes, and may be asymptomatic or manifest with hypogonadism, galactorrhoea, infertility, or mass-effect symptoms depending on the degree and duration of elevation. The diagnosis requires exclusion of transient physiological elevation and laboratory artefacts, including macroprolactinaemia and the high-dose hook effect, before attributing the finding to a structural lesion such as a prolactinoma.

IN PLAIN ENGLISH

Hyperprolactinaemia means having a higher-than-normal level of prolactin, a hormone made by the pituitary gland that is best known for stimulating breast milk production. It matters because persistently high prolactin can disrupt sex hormones, leading to irregular periods, infertility, breast milk leakage, and thinning of the bones in both women and men.

COMMON MISCONCEPTION / WHAT IT DOES NOT MEAN

Hyperprolactinaemia is NOT equivalent to a diagnosis of prolactinoma. Many physiological states, medications, and non-tumoural conditions elevate prolactin, and a substantial proportion of cases are idiopathic; the finding of an elevated prolactin level requires systematic exclusion of these causes before a pituitary tumour is assumed.

🔤

Word Breakdown

hyper-

=above, excessive

prolact-

=prolactin (from pro- + lact-, milk, referring to the hormone's lactogenic action)

-inaemia

=condition of the blood (from Greek haima, blood)

Literal Meaning: An excess of prolactin in the blood

🏷️

Abbreviations

PRL=Prolactin — the anterior pituitary hormone measured to establish the diagnosis

HPL=Hyperprolactinaemia — abbreviation used in some clinical literature and notes

🔄

Synonyms & Variants

Hyperprolactinemia›Prolactin excess›

🎯

Category-Specific Context

Hyperprolactinaemia is classified as a Disease because it denotes a defined biochemical abnormality with recognised thresholds, aetiologies, and clinical consequences, rather than a symptom or sign. Its severity ranges from asymptomatic mild elevation, often drug-induced or idiopathic, to marked elevation associated with prolactin-secreting pituitary adenomas; the clinical framework distinguishes physiological, pharmacological, pathological (hypothalamic-pituitary and systemic), and idiopathic categories.

🏥

Clinical Context & Usage

CLINICAL SETTINGS

Endocrinology Outpatient ClinicGeneral Medicine WardGynaecology ClinicReproductive Medicine ClinicPsychiatry ClinicEmergency Department

USAGE & DOCUMENTATION NOTES

In clinical documentation, hyperprolactinaemia is typically recorded with the serum value and the assay units, for example "prolactin 85 micrograms/L (reference <25)". Clinicians specify whether the sample was taken under basal conditions, because stress, venepuncture, and nipple stimulation can transiently elevate prolactin. The term is frequently used in referral letters to endocrinology or gynaecology alongside the presenting syndrome, such as "hyperprolactinaemia with amenorrhoea and galactorrhoea". When drug-induced aetiology is suspected, the responsible agent and its temporal relationship to prolactin measurement are documented.

🔬

Primary Causes & Pathophysiology

PATHOPHYSIOLOGY

Prolactin is a 199-amino-acid polypeptide synthesised and secreted by lactotroph cells of the anterior pituitary. Its secretion is under dominant tonic inhibition by dopamine released from hypothalamic tuberoinfundibular neurons into the hypophyseal portal circulation, which acts on dopamine D2 receptors on lactotrophs. Hyperprolactinaemia arises when this inhibitory control is disrupted at any level: lactotroph adenomas autonomously secrete prolactin; hypothalamic or pituitary-stalk lesions impair dopamine delivery to the anterior pituitary; dopamine D2 receptor antagonists block the inhibitory signal; and primary hypothyroidism increases hypothalamic thyrotropin-releasing hormone (TRH), a potent prolactin-releasing factor. Elevated prolactin suppresses gonadotropin-releasing hormone (GnRH) pulsatility, reducing luteinising hormone and follicle-stimulating hormone secretion and producing hypogonadotrophic hypogonadism. This sex-steroid deficiency accounts for the reproductive and skeletal consequences of sustained hyperprolactinaemia.

PRIMARY CAUSES

Prolactinoma

A benign lactotroph adenoma secretes prolactin autonomously, escaping normal dopaminergic inhibition; prolactin levels often correlate with tumour size, with microadenomas typically producing modest elevations and macroadenomas producing marked elevations.

Hypothalamic or pituitary-stalk lesions (non-functioning pituitary adenoma, craniopharyngioma, meningioma, infiltrative disease, stalk injury)

Disruption of dopamine transport from the hypothalamus to the anterior pituitary via the portal circulation removes tonic inhibition of lactotrophs, producing modest prolactin elevation typically below 100–200 micrograms/L.

Primary hypothyroidism

Reduced thyroid hormone feedback increases hypothalamic TRH, which stimulates lactotrophs to release prolactin in addition to thyrotrophs; up to 20–40% of patients with hypothyroidism have hyperprolactinaemia depending on severity.

Chronic kidney disease

Reduced renal clearance of prolactin, which is partly eliminated by the kidney, contributes to mild-to-moderate sustained elevation.

Cirrhosis

Altered hepatic clearance and hypothalamic-pituitary axis dysregulation in advanced liver disease contribute to mild prolactin elevation.

Chest wall lesions or stimulation (trauma, surgery, herpes zoster, nipple piercing)

Afferent neural pathways from the chest wall stimulate hypothalamic prolactin-releasing mechanisms, producing transient or mild elevation.

💊

Drug-Induced Causes

💊 Antipsychotics — typical (haloperidol, chlorpromazine, fluphenazine, thioridazine) and atypical (risperidone, paliperidone, amisulpride) ↗

Mechanism: Dopamine D2 receptor antagonism in the tuberoinfundibular pathway removes tonic inhibition of lactotroph prolactin secretion; risperidone and typical antipsychotics are associated with the most marked elevations, sometimes exceeding 200 micrograms/L.

→ Review the antipsychotic indication and consider switching to a prolactin-sparing agent (e.g., aripiprazole, quetiapine, clozapine) in consultation with psychiatry when clinically appropriate; do not abruptly discontinue antipsychotic treatment. Monitor for hypogonadal and bone complications if elevation persists.

💊 Antiemetics / prokinetics — metoclopramide, domperidone, prochlorperazine ↗

Mechanism: Dopamine D2 receptor blockade at the pituitary lactotroph and at central sites increases prolactin secretion; metoclopramide can produce elevations exceeding 200 micrograms/L.

→ Consider alternative antiemetic agents where feasible; avoid prolonged use of dopamine-antagonist antiemetics when hyperprolactinaemia is symptomatic.

💊 Tricyclic antidepressants and selective serotonin reuptake inhibitors ↗

Mechanism: These agents may elevate prolactin through serotonergic modulation of hypothalamic prolactin-regulating pathways, though elevations are generally mild.

→ Interpret prolactin in the context of the treated condition; consider alternative agents only when clinically justified and after psychiatric consultation.

💊 Oestrogens (including combined hormonal contraceptives and hormone replacement therapy) ↗

Mechanism: Oestrogen directly stimulates lactotroph proliferation and prolactin synthesis and secretion.

→ Review the indication for oestrogen therapy; prolactin typically falls after discontinuation if no other cause is present.

💊 Verapamil, methyldopa, reserpine ↗

Mechanism: These cardiovascular agents interfere with dopaminergic regulation of prolactin secretion at central or pituitary levels, producing mild elevation.

→ Consider alternative antihypertensive agents where clinically appropriate and monitor prolactin if symptoms develop.

💊 Opioids and illicit drugs (cannabis, cocaine) ↗

Mechanism: Opioids and other centrally acting agents modulate hypothalamic dopaminergic pathways, reducing dopamine-mediated inhibition of prolactin release.

→ Address substance use where relevant; prolactin may normalise with cessation, but persistent elevation requires further evaluation.

🌍

Epidemiology

Prevalence:The prevalence of hyperprolactinaemia in the general adult population is reported to be less than 1%, rising to approximately 5% in family-planning clinic populations, 9% among women with amenorrhoea, and 25% among women with galactorrhoea; among women with both amenorrhoea and galactorrhoea, approximately 70% are hyperprolactinaemic. Clinically apparent prolactinomas have a reported prevalence ranging from approximately 6–10 to 50 per 100,000, with mean estimates of approximately 30 per 100,000 in women and 10 per 100,000 in men, and peak prevalence in women aged 25–34 years.

Age Group:Hyperprolactinaemia can occur at any age. Prolactinomas are most frequently diagnosed in women of reproductive age (typically 25–40 years), in whom microadenomas predominate, whereas men are more often diagnosed after the age of 40–50 years, frequently with macroadenomas. Children and adolescents may be affected, although prolactinomas are rare in this group; boys may present with delayed puberty or hypogonadism and girls with menstrual disturbance or galactorrhoea.

Sex Predilection:Female

Geographic Distribution:No consistent, clinically meaningful geographic variation in the occurrence of hyperprolactinaemia itself has been established; the distribution of aetiologies may vary with local prescribing patterns, availability of dopamine-antagonist antipsychotics, and access to pituitary imaging. Prolactinoma incidence appears broadly comparable across populations studied in Europe, North America, and Asia, although ascertainment differs by healthcare setting.

Red Flags & Triage ★

TRIAGE LEVEL

🚨 ROUTINE

DO NOT MISS — LIFE-THREATENING PRESENTATIONS

A pituitary macroadenoma with visual field defect or headache and a normal or modestly elevated prolactin — consider the high-dose hook effect and request reassay of diluted serum before excluding a macroprolactinoma.
Marked hyperprolactinaemia with hypogonadism and bone loss in a patient with a history of antipsychotic use — recognise drug-induced hyperprolactinaemia as a cause of potentially irreversible skeletal morbidity and address the underlying medication where clinically feasible.

URGENT EVALUATION TRIGGERS

Headache with a new visual field defect or visual loss in a patient with known or suspected pituitary adenoma — requires urgent neuro-ophthalmic and endocrine assessment for possible apoplexy or mass effect.
Sudden severe headache with diplopia, ptosis, or altered consciousness in a patient with a pituitary lesion — consider pituitary apoplexy as an emergency.
Severe symptomatic hypogonadism or infertility with markedly elevated prolactin — warrants prompt endocrine referral for diagnosis and treatment, though not an emergency in the absence of mass effect.

Contraindications & Precautions

SPECIAL PRECAUTIONS

Do not diagnose hyperprolactinaemia on a single sample obtained after venepuncture stress or nipple stimulation; repeat under basal
rested conditions before committing to further investigation.
Exclude macroprolactinaemia with polyethylene glycol precipitation or an equivalent method when the clinical picture is discordant with the reported prolactin level
because macroprolactin is biologically inactive and may produce apparent hyperprolactinaemia.
Suspect the high-dose hook effect when a very large pituitary macroadenoma is accompanied by a normal or only modestly elevated prolactin; request reassay after serial dilution.
Before attributing hyperprolactinaemia to a drug
review the full medication list
including antipsychotics
antiemetics
antidepressants
oestrogens
and antihypertensives
and consider the temporal relationship.
When cabergoline is used at higher cumulative doses or for prolonged periods
particularly in patients with additional cardiac risk factors
remain alert to the potential for valvular heart disease and consider echocardiographic surveillance according to local protocols; the doses used for hyperprolactinaemia are generally far lower than those associated with valvulopathy in Parkinson's disease.

Complications

DOWNSTREAM CLINICAL COMPLICATIONS

Hypogonadotrophic hypogonadism — suppression of GnRH pulsatility reduces sex-steroid production
causing menstrual disturbance and infertility in women and sexual dysfunction
low libido
and impaired spermatogenesis in men.
Osteoporosis and bone loss — sustained sex-steroid deficiency reduces bone mineral density; spinal bone density may be decreased by approximately 25% in women with hyperprolactinaemia and may not fully recover with prolactin normalisation.
Galactorrhoea — non-puerperal breast milk secretion
which may be distressing and is more common in women but can occur in men.
Infertility — anovulation in women and impaired spermatogenesis or erectile dysfunction in men.
Mass effects from an underlying macroadenoma — headache
visual field defects (typically bitemporal hemianopia)
and hypopituitarism from compression of adjacent pituitary tissue or the optic chiasm.

📏

Reference Ranges

NORMAL RANGESerum prolactin reference ranges vary by laboratory and sex; commonly cited adult upper limits are approximately 25 micrograms/L (1087 pmol/L) in women and 20 micrograms/L (870 pmol/L) in men, with many laboratories reporting an upper limit of 15–20 micrograms/L for both sexes.

UNIT OF MEASUREMENTmicrograms/L (ng/mL); pmol/L or mIU/L are also used by some laboratories

🔀

Confused With (LASA & DDx) ★

LEXICAL (LASA) — SIMILAR NAMES

Hyperprolactinaemia vs. hyperproliferative

The prefix "hyperprolact-" is sometimes misread or misheard as "hyperproliferat-"; hyperprolactinaemia refers to elevated prolactin, whereas hyperproliferative describes increased cell proliferation and is unrelated.

CLINICAL DIFFERENTIAL DIAGNOSES (DDx)

Macroprolactinaemia

Key Distinguishing Feature: Prolactin is elevated on immunoassay but symptoms are absent or discordant; polyethylene glycol precipitation or gel filtration demonstrates that the circulating prolactin is predominantly macroprolactin (immunoglobulin-bound), which is biologically inactive.

High-dose hook effect

Key Distinguishing Feature: A very large pituitary macroadenoma is present but the reported prolactin is unexpectedly low or normal; reassay of diluted serum reveals markedly elevated prolactin, confirming that antigen excess produced a falsely low result.

Normoprolactinaemic galactorrhoea

Key Distinguishing Feature: Galactorrhoea occurs with serum prolactin within the reference range; alternative mechanisms such as chest wall stimulation, drug effects, or idiopathic galactorrhoea should be considered.

Physiological hyperprolactinaemia

Key Distinguishing Feature: Elevation is transient and attributable to pregnancy, lactation, nipple stimulation, exercise, stress, or sleep; repeat testing under basal conditions normalises the value.

💎

Clinical Pearls

💎

A single elevated prolactin should not be over-interpreted: venepuncture stress, recent nipple stimulation, sleep, and exercise can all raise prolactin transiently. Repeat the measurement under basal, rested conditions before embarking on imaging or a diagnostic label.

💎

The magnitude of prolactin elevation is diagnostically informative: drug-induced and stalk-effect hyperprolactinaemia typically produce modest elevations (usually below 100–200 micrograms/L), whereas prolactinomas — especially macroadenomas — often produce values well above 200–250 micrograms/L, although atypical antipsychotics such as risperidone can also exceed 200 micrograms/L.

💎

When a large pituitary macroadenoma is accompanied by a normal or only mildly elevated prolactin, the high-dose hook effect must be excluded by requesting prolactin measurement on serially diluted serum; failure to do so can lead to a missed diagnosis of macroprolactinoma and inappropriate surgery.

💎

Macroprolactinaemia is a common analytical cause of apparent hyperprolactinaemia; it should be considered particularly when the clinical picture is discordant with the biochemical result, and polyethylene glycol precipitation is a practical screening method.

💎

In women, hyperprolactinaemia should be considered in the evaluation of amenorrhoea, oligomenorrhoea, infertility, and galactorrhoea; in men, the presentation is often more insidious, with reduced libido, erectile dysfunction, and hypogonadism, which may delay diagnosis until a macroadenoma has developed.

💎

Dopamine agonist therapy with cabergoline is first-line for most symptomatic prolactinomas and drug-induced hyperprolactinaemia when the offending drug cannot be stopped; however, at the much lower doses used for hyperprolactinaemia, the valvulopathy risk associated with high-dose cabergoline in Parkinson's disease is substantially attenuated, and routine echocardiography is not universally required.

📝

Example Usage & SOAP

CLINICAL SENTENCE

""Serum prolactin was 112 micrograms/L (reference <25) on a basal sample; macroprolactin was excluded by polyethylene glycol precipitation, and pituitary MRI demonstrated a 6 mm right-sided microadenoma consistent with a prolactinoma.""

IN A SOAP NOTE

S: A 29-year-old woman presents with 8 months of irregular menses and 3 months of bilateral breast milk secretion; she is not pregnant or breastfeeding. O: Vital signs normal. Breast examination shows expressible milky discharge from both nipples; visual fields normal. Serum prolactin 98 micrograms/L (reference <25); TSH and free T4 normal; beta-hCG negative. A repeat basal prolactin is 105 micrograms/L. Pituitary MRI with gadolinium shows a 5 mm left microadenoma. A: Hyperprolactinaemia secondary to a microprolactinoma, with galactorrhoea and oligomenorrhoea. P: Start cabergoline 0.25 mg twice weekly; repeat prolactin in 4–6 weeks; counsel regarding contraception and pregnancy planning; monitor for symptomatic improvement.

DIFFERENTIAL DIAGNOSIS CONTEXT

Differential diagnosis for hyperprolactinaemia: (1) Physiological — repeat under basal conditions; pregnancy, lactation, stress, and nipple stimulation excluded by history. (2) Drug-induced — review antipsychotics, antiemetics, antidepressants, oestrogens, and antihypertensives; consider switching prolactin-sparing agents when appropriate. (3) Macroprolactinaemia — screen with polyethylene glycol precipitation when symptoms are absent or discordant with the level. (4) Pituitary stalk or hypothalamic lesion — consider non-functioning adenoma, craniopharyngioma, or infiltrative disease; prolactin typically modestly elevated. (5) Prolactinoma — usually prolactin >100–200 micrograms/L, with MRI correlation; exclude hook effect in large macroadenomas. (6) Primary hypothyroidism and chronic kidney disease — check TSH, free T4, and renal function.

📈

Prognosis

SHORT-TERM OUTCOME

Short-term prognosis depends on aetiology. Drug-induced hyperprolactinaemia typically resolves after discontinuation or substitution of the responsible agent, though normalisation may take weeks to months. Idiopathic hyperprolactinaemia may remain stable or resolve spontaneously. Prolactinomas usually respond to dopamine agonist therapy with prolactin normalisation and tumour shrinkage, but the time course varies with tumour size and individual responsiveness.

LONG-TERM PROGNOSIS

Long-term outcome is generally favourable for microprolactinomas, which rarely progress to macroadenomas and often remain stable over years. However, population-based registry data indicate that prolactinoma as a whole is associated with modest excess all-cause mortality (standardised mortality ratio approximately 1.21, 95% CI 1.03–1.41), with heterogeneity across patient profiles: excess mortality appears concentrated in older, male-predominant patients with larger tumours, whereas younger women with small tumours do not show excess mortality in some analyses. Sustained hypogonadism and bone loss may persist even after biochemical cure, and long-standing hyperprolactinaemia has been associated with adverse metabolic and skeletal outcomes.

📚

References & Coding

ICD-10 DIAGNOSTIC CODE

E22.1

LITERATURE CITATIONS & GUIDELINES

[1]Melmed S, Casanueva FF, Hoffman AR, Kleinberg DL, Montori VM, Schlechte JA, Wass JA. Diagnosis and treatment of hyperprolactinemia: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2011;96(2):273-288. doi:10.1210/jc.2010-1692

[2]Petersen S, Fleseriu M, Casanueva FF, Giustina A, Biermasz N, Biller BMK, et al. Diagnosis and management of prolactin-secreting pituitary adenomas: a Pituitary Society International Consensus Statement. Nat Rev Endocrinol. 2023;19(12):722-740. doi:10.1038/s41574-023-00886-5

[3]BMJ Best Practice. Assessment of hyperprolactinaemia. BMJ Publishing Group; accessed 2026.

[4]StatPearls. Hyperprolactinemia. National Library of Medicine; accessed 2026.

MEDICAL DISCLAIMER — This content is intended for educational purposes and qualified healthcare professionals only. Always refer to current clinical diagnostic criteria, institutional protocols, and official guidelines. Medobo is not responsible for clinical decisions made based on this content.